Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748157 | 1.00 | TACR1 (0.87) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5748160 | 1.00 | TACR1 (0.87) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19031858 | 1.00 | TACR1 (0.87) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4100443 | 0.94 | TACR1 (0.85) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4100441 | 0.94 | TACR1 (0.85) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL24403434 | 0.93 | TACR1 (1.00) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4102176 | 0.93 | TACR1 (1.00) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5005159 | 0.93 | TACR1 (1.00) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5006366 | 0.93 | TACR1 (1.00) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4102172 | 0.93 | TACR1 (1.00) | TACR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324832-B2 | Tripartite modulators of endosomal G protein-coupled receptors | ENDOSOME THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20190000981-A1 | TRIPARTITE MODULATORS OF ENDOSOMAL G PROTEIN-COUPLED RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000981-A1 | TRIPARTITE MODULATORS OF ENDOSOMAL G PROTEIN-COUPLED RECEPTORS | NTSR1, NTSR2, MRGPRX2 | TACR1 16/4885CYP3A4 4089/4885CYP2D6 4086/4885 |
| US-11324832-B2 | Tripartite modulators of endosomal G protein-coupled receptors | NTSR1, NTSR2, MRGPRX2 | TACR1 16/4885CYP3A4 4089/4885CYP2D6 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.